Corvus Pharmaceuticals Inc (CRVS) Implied Volatility Current

Tracking CRVS implied volatility helps you identify when options premiums on Corvus Pharmaceuticals Inc are historically cheap or expensive, and where the best trades are hiding. Corvus Pharmaceuticals Inc implied volatility reflects the market's expectation of future price movement: when CRVS IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Corvus Pharmaceuticals Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For CRVS, tracking metrics like CRVS IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on CRVS signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.

Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where CRVS implied volatility sits today versus where it has been. Our scanner ranks Corvus Pharmaceuticals Inc implied volatility against its historical range, surfaces extremes in CRVS IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Corvus Pharmaceuticals Inc IV is rich or cheap — measure it, then act on it.